TheJakartaPost
Please Update your browser
Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.
Daewoong Pharmaceutical says anti-parasitic drug effective against coronavirus in animal tests
Change Size
This handout illustration image obtained Feb. 27, 2020 courtesy of the National Institutes of Health taken with a transmission electron microscope shows SARS-CoV-2, the virus that causes COVID-19, isolated from a patient in the US, as Virus particles are shown emerging from the surface of cells cultured in the lab - the spikes on the outer edge of the virus particles give coronaviruses their name, crown-like. South Korea's Daewoong Pharmaceutical said its anti-parasitic drug niclosamide had eliminated the novel coronavirus from animals' lungs during testing. (AFP/Handout / National Institutes of Health)
S
outh Korea's Daewoong Pharmaceutical said its anti-parasitic drug niclosamide had eliminated the novel coronavirus from animals' lungs during testing.
Drugmakers worldwide are rushing to develop treatments for the illness caused by the new coronavirus, which has killed more than 400,000 globally since it first emerged late last year in China.
Daewoong said its experimental anti-viral drug completely cleared up the disease in ferrets' lung tissues and inhibited inflammation. The company plans to start human clinical trials in July.
Three other companies around the world are testing niclosamide as a coronavirus treatment, but Daewoong is the only one that offers the drug in a form that is not given orally, the company official told Reuters.
The company tested the drug on ferrets for around three months.
"Based on the positive outcome of the animal test, we plan to complete human trials and get approval of the COVID-19 treatment drug by the end of this year," said Jeon Seng-ho, CEO of Daewoong Pharma.
There is no treatment for COVID-19 and human trials of several other antiviral drugs have not shown conclusive benefits.
Shares in Daewoong Pharma jumped 48.2% in three trading days after last week's announcement, as of Tuesday.
